PREPL

Across TCGA pan-cancer cohorts, PREPL Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PREPL data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher PREPL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PREPL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PAAD, UCEC, and BLCA are the cancer types where PREPL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	DFS	Median	All	0.068	0.484	<.001	24	view →
UCEC	DFS	Median	II,III,IV	0.922	0.435	.023	12	view →
BLCA	OS	Median	IV	0.052	0.575	<.001	6	view →
LUAD	OS	Median	III,IV	0.057	0.680	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PREPL–PAAD (DFS)

Open the PAAD breakdown →